Weekly Digest – February 2025 Weekly Digest – February 2025 14 Feb 2025: 1st Trop-2 ADC Trodelvy expands indication to metastatic HR+/HER2- breast cancer Trodelvy (Sacituzumab govitecan) received expanded approval in Korea to treat metastatic HR+/HER2- breast cancer resistant to […]
Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Datopotamab deruxtecan recommended for approval in the EU by CHMP for patients with previously treated metastatic HR-positive, HER2-negative breast cancer Datopotamab deruxtecan has been recommended for approval […]
Weekly Digest – February 2025 Weekly Digest – February 2025 31 Jan 2025: Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU The FDA approved a label expansion for […]
